CCK, Not Insulin: Preclinical Links Between Obesity and Pancreatic Cancer

In obesity-associated pancreatic ductal adenocarcinoma (PDAC) models, investigators report that a subset of pancreatic beta cells in obese mice shifted away from an insulin-focused state and instead produced cholecystokinin (CCK). The authors frame this observation as challenging prior explanations that emphasized excess insulin secretion as a key endocrine driver of obesity-linked pancreatic cancer risk. They describe CCK production as occurring “inappropriately” in response to obesity and present it as the hormone signal most directly connected to PDAC phenotypes in their mouse systems. The report situates these findings in preclinical settings and describes multiple evidence types used to connect beta-cell hormone-state changes with PDAC development in mice.

The proposed origin of these CCK-producing beta cells is described as coming from a computational trajectory analysis applied to single-cell state changes over time. Using TrajectoryNet, the investigators report tracing a transition in which cells characterized as “healthy,” insulin-producing beta cells gave rise to beta cells that expressed CCK as obesity progressed. In parallel, the authors describe an observed correlation between CCK expression and intracellular stress-marker findings within beta cells in obese mice, presented as a stress-context–associated state shift rather than a fixed beta-cell subtype. Together, the trajectory and correlation results are presented as supporting a model in which obesity-associated stress accompanies a beta-cell transition toward CCK expression in these mouse experiments.

Interventional experiments are reported as testing whether changing CCK levels tracks with PDAC phenotypes in mouse models, including increasing beta-cell CCK in lean mice and reducing CCK production in obese mice via gene knockout. In the study’s CCK loss- and gain-of-function experiments, the authors report that eliminating CCK production in obese mice via gene knockout was associated with a marked reduction in tumor growth, while increasing beta-cell–derived CCK in lean mice was reported to be sufficient to promote PDAC development. The investigators describe these complementary directions of effect as supporting “necessary and sufficient” roles for CCK within the boundaries of the preclinical systems evaluated. The report presents these manipulations as causal-supporting tests that move beyond descriptive associations in the mouse models.

Alongside the hormone-state and intervention findings, the authors describe endocrine–exocrine interactions in the pancreas as part of their proposed framework. They report that as beta cells changed state, exocrine pancreatic cells also transformed in the models, coinciding with exocrine cells becoming more susceptible to tumor development and positioning crosstalk between compartments as a feature of the observed phenotype. The authors suggest that endocrine–exocrine signaling pathways (including CCK-related signals) could be explored as a potential future direction for pancreatic cancer prevention research, while the current evidence remains grounded in mouse-based findings. Overall, the report positions CCK as a candidate mechanistic signal and a candidate biomarker/target hypothesis emerging from preclinical observations and manipulations.

Key Takeaways:

• In obese mouse models, a subset of pancreatic beta cells was reported to express CCK, which the authors frame as an alternative to insulin-centric explanations of obesity-associated PDAC risk.
• Trajectory and correlation analyses were described as tracing CCK-expressing beta cells back to insulin-producing beta cells and linking CCK expression with cellular stress-marker findings in obese mice.
• CCK loss- and gain-of-function experiments in mice were reported to support necessity/sufficiency framing, and the authors note that circulating CCK may be measurable and could potentially serve as a risk marker; they also suggest endocrine–exocrine signaling as a possible area for future prevention research.